Drug Profile
Research programme: pain and migraine therapy - OptiNose
Alternative Names: OPT 1005Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator OptiNose AS
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Migraine; Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Migraine in United Kingdom (Intranasal, Spray)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in United Kingdom (Intranasal, Spray)